$10.48
Iovance Biotherapeutics is a biotechnology business based in the US. Iovance Biotherapeutics shares (IOVA) are listed on the NASDAQ and all prices are listed in US Dollars. Iovance Biotherapeutics employs 557 staff and has a trailing 12-month revenue of around $32.8 million.
Our top picks for where to buy Iovance Biotherapeutics stock
How to buy Iovance Biotherapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – IOVA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Iovance Biotherapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Iovance Biotherapeutics stock price (NASDAQ: IOVA)
Use our graph to track the performance of IOVA stocks over time.Iovance Biotherapeutics shares at a glance
Latest market close | $10.85 |
---|---|
52-week range | $3.21 - $18.33 |
50-day moving average | $9.16 |
200-day moving average | $10.02 |
Wall St. target price | $24.42 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.67 |
Is it a good time to buy Iovance Biotherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Iovance Biotherapeutics price performance over time
Historical closes compared with the close of $10.85 from 2024-09-03
1 week (2024-08-29) | -4.66% |
---|---|
1 month (2024-08-05) | 46.23% |
3 months (2024-06-05) | 30.41% |
6 months (2024-03-05) | -34.20% |
1 year (2023-09-05) | 79.64% |
---|---|
2 years (2022-09-01) | N/A |
3 years (2021-09-03) | 25.1 |
5 years (2019-09-05) | 21.03 |
Iovance Biotherapeutics financials
Revenue TTM | $32.8 million |
---|---|
Gross profit TTM | $0 |
Return on assets TTM | -33.35% |
Return on equity TTM | -65.36% |
Profit margin | 0% |
Book value | $2.59 |
Market Capitalization | $3.5 billion |
TTM: trailing 12 months
Iovance Biotherapeutics share dividends
We're not expecting Iovance Biotherapeutics to pay a dividend over the next 12 months.
Have Iovance Biotherapeutics's shares ever split?
Iovance Biotherapeutics's shares were split on a 1:100 basis on 25 September 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Iovance Biotherapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Iovance Biotherapeutics shares which in turn could have impacted Iovance Biotherapeutics's share price.
Iovance Biotherapeutics share price volatility
Over the last 12 months, Iovance Biotherapeutics's shares have ranged in value from as little as $3.21 up to $18.33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iovance Biotherapeutics's is 0.627. This would suggest that Iovance Biotherapeutics's shares are less volatile than average (for this exchange).
Iovance Biotherapeutics overview
Iovance Biotherapeutics, Inc. , a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc. ; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.
Frequently asked questions
What percentage of Iovance Biotherapeutics is owned by insiders or institutions?Currently 0.504% of Iovance Biotherapeutics shares are held by insiders and 87.411% by institutions. How many people work for Iovance Biotherapeutics?
Latest data suggests 557 work at Iovance Biotherapeutics. When does the fiscal year end for Iovance Biotherapeutics?
Iovance Biotherapeutics's fiscal year ends in December. Where is Iovance Biotherapeutics based?
Iovance Biotherapeutics's address is: 825 Industrial Road, San Carlos, CA, United States, 94070 What is Iovance Biotherapeutics's ISIN number?
Iovance Biotherapeutics's international securities identification number is: US4622601007 What is Iovance Biotherapeutics's CUSIP number?
Iovance Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 37182R102
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question